Teva Pharmaceutical Industries Ltd ADR Stock
We can see a decrease in the price for Teva Pharmaceutical Industries Ltd ADR. Compared to yesterday it has lost -€0.500 (-1.860%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 28 € there is a slightly positive potential of 6.06% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 26.4 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -1.860% | -1.493% | 13.793% | 26.923% | -1.859% | 208.411% | 238.896% |
| Bayer AG ADR | -0.570% | 0.571% | 6.024% | 88.841% | - | -26.050% | -26.667% |
| Roche Holding AG ADR | -0.290% | -1.273% | 4.868% | 28.892% | 0.318% | 19.815% | 24.453% |
| Astrazeneca ADR | -0.630% | 0.000% | 0.641% | 21.705% | -0.633% | 23.817% | 88.702% |
Comments
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat